Headlines

Go To Pro Hockey Rumors
Go To Hoops Rumors

Jose Leclerc

Post-Tommy John Players That Could Impact 2023

By | at

News items about Tommy John surgeries are fairly commonplace in baseball circles, but there’s no doubting it’s a significant event for the impacted player. It usually takes over a year to return to form, with a multi-stage rehabilitation process required to regain functionality.

Once a player gets back into game shape, there’s no guarantee the results will be the same. Justin Verlander looked just as good as ever in 2022, but Mike Clevinger didn’t get his velocity all the way back and saw his strikeout rate dip. He could still take another step forward in 2023 now that he’s another year removed from the procedure, but it goes to show that there are no guarantees about what happens in the aftermath.

Here are some players who went under the knife over the past year or so and who will be looking for good progress in 2023, both for their teams and themselves. Huge shoutout to the Tommy John Surgery list for having these details and so much more.

Forrest Whitley, Astros — Surgery Date: March 2021

Whitley, 25, was once considered one of the best pitching prospects in baseball, but his progress has been stalled by various factors. He missed 50 games in 2018 due to a drug suspension, and injuries have hampered him in the years since. He returned from his layoff late last year and tossed 40 innings in the minors but walked 14.5% of batters faced. The Astros already have a great rotation without him, but if Whitley could get back to the form that made him such a hyped prospect, they would be even more loaded.

Kirby Yates, Braves — March 2021

Yates, 36 in March, was one of the best relievers in the league in 2018 and 2019, arguably the best. He posted a 1.67 ERA over 125 games, striking out 38.7% of batters faced, walking just 6.1% of them and getting grounders on 45.2% of balls in play. Since then, however, he’s thrown just 11 1/3 innings. Seven of those came late in the 2022  season, though Yates gave up four runs on six hits and five walks in seven innings. This will be his first full season back. The Braves have a strong bullpen even if Yates can’t get back to peak form, but they’ll likely be in a tight division race and that kind of elite stuff would provide a nice boost.

José Leclerc and Jonathan Hernández, Rangers — March and April 2021, respectively

Leclerc, 29, seemed to be establishing himself as an excellent reliever in 2018. He got into 59 games for the Rangers and posted a 1.56 ERA, getting 12 saves and 15 holds in the process. A .211 BABIP surely helped, but there was a lot to like. He took a step back in 2019 with a 4.33 ERA and then missed most of the following two years. Leclerc returned in June of last year and struggled at first before posting a 2.01 ERA from July onwards. Hernández had a 2.90 ERA in 2020 before missing the 2021 campaign. He returned last year and posted a 2.97 ERA, but with concerning peripherals. His 6.4% walk rate from the former campaign jumped to 13% while his strikeout rate fell from 24.8% to 20.6%. On the more encouraging side, his ground ball rate went from 45.7% to 62.4%. The Rangers totally overhauled their rotation without doing much to the bullpen, but they could potentially get a boost from within if Leclerc and/or Hernández look good this year.

Adrián Morejón, Padres — April 2021

Once considered a top pitching prospect, Morejón, 24 next month, has been slowed by various injuries. He returned in 2022 but worked only in relief, tossing 34 innings in the majors and 13 1/3 in the minors. The Padres have some uncertainty in the back of their rotation that Morejón could help with if he stays healthy, but he’ll likely have workload concerns after so much missed time.

James Paxton, Red Sox — April 2021

Paxton, 34, had a great four-year run with the Mariners and Yankees from 2016 to 2019. However, he’s hardly pitched over the last three years due to various arm issues. He got back on the mound last summer while attempting to come back from Tommy John but then suffered a lat tear that halted his comeback effort. The Red Sox then had the choice to trigger a two-year option on the lefty worth $26MM, which they turned down based on his uncertain health outlook. He then had a $4MM player option that he triggered and will be with the Sox for 2023. He and Chris Sale would have made for a formidable one-two punch at the top of a rotation a few years ago, but neither has been healthy and effective for quite some time. Their status this year figures to have a huge impact on the fortunes of the Sox for the upcoming campaign.

Dustin May, Dodgers — May 2021

May, 25, returned late last year and was able to make six starts for the Dodgers. He posted a 4.50 ERA in that time and struck out 22.8% of batters faced, with both of those numbers paling in comparison to his pre-surgery form. The Dodgers let Tyler Anderson and Andrew Heaney depart from their 2022 rotation, while bringing in Noah Syndergaard. The quiet offseason will be easier to accept if May can post results like he did over 2019-2021: 2.93 ERA, 24.2% strikeout rate, 5.9% walk rate, 51.6% ground ball rate.

Joey Lucchesi, Mets — June 2021

Lucchesi, 30 in June, made 56 starts for the Padres in 2018 and 2019 with a 4.14 ERA. He didn’t get much of an opportunity in 2020 and was flipped to the Mets as part of the Joe Musgrove trade. He isn’t one of the club’s five best starters right now, but their rotation features four veterans who are 34 or older in Verlander, Max Scherzer, Carlos Carrasco and José Quintana. Also, Kodai Senga is making the transition from Japan, where starters frequently only pitch once a week. The club will surely need to rely on its depth this year at some point, making Lucchesi a key part of the equation.

Spencer Turnbull, Tigers — July 2021

Turnbull, 30, was seeming to make progress towards being a quality starter for the Tigers. He posted a 4.61 ERA in 2019 but got that down to 3.97 in 2020. He pushed it down even more in 2021, registering a 2.88 ERA over nine starts before getting shut down and requiring surgery. The Tigers seem likely to be without Casey Mize and Tarik Skubal to start the year as those pitchers deal with their own injuries. That could leave a path for Turnbull to get back on track.

Tyler Glasnow, Rays — August 2021

Glasnow, 29, didn’t live up to expectations with the Pirates but made good on his prospect pedigree after getting traded to the Rays. From 2019 to 2021, he had a 2.80 ERA while striking out 35.9% of batters faced and walking just 7.8% of them. Tommy John surgery put him out of action for a while but he was able to return late last year, making two starts in the regular season and one in the postseason. Glasnow has looked like an ace at times but still hasn’t maintained it over an extended stretch, still never reaching 115 innings in a major league season. The Rays have been fairly quiet this winter, but a healthy Glasnow is arguably a bigger upgrade to their roster than any move they could have made.

Tejay Antone, Reds — August 2021

Antone, 29, debuted in 2020 and was excellent out of the Reds’ bullpen. Over that year and 2021, he tossed 69 innings with a 2.48 ERA, 32.3% strikeout rate and 48% ground ball rate. The walks were a little high at 10.8% but he was still able to be incredibly effective regardless. He isn’t slated to reach free agency until after 2025, but the rebuilding Reds might have to consider a deadline deal if Antone is healthy and pitching well this summer.

Garrett Crochet, White Sox — April 2022

Crochet, 24 in June, was selected 11th overall in the 2020 draft and made his MLB debut later that year. Between his five appearances in 2020 and 54 more the following year, he has a 2.54 ERA and 29% strikeout rate. He’ll likely miss at least part of the upcoming campaign but the club is planning on keeping him in a relief role, which could help him return quicker.

Luke Jackson, Giants — April 2022

Jackson, 31, had a huge breakout with the Braves in 2021. He tossed 63 2/3 innings with a 1.98 ERA, striking out 26.8% of batters faced while getting grounders at a healthy 52.5% clip. He wasn’t as effective in the playoffs but nonetheless was part of the club’s World Series victory that year. He reached free agency and signed with the Giants, who are taking a shot on a return to form, though Jackson might miss the first couple of months of the 2023 season.

John Means, Orioles — April 2022

Means, 30 in April, was one of the few highlights for the Orioles during their leanest rebuilding years. He has a 3.81 ERA in 356 2/3 career innings, keeping his walks down to an excellent 5% rate. The Orioles took a huge step forward last year, graduating many of their top prospects and actually flirting with postseason contention. They’ll be looking to make more progress this year, but the rotation is still lacking in proven options. Getting Means back into the mix would be a big help if some of the younger guys struggle.

Chris Paddack, Twins — May 2022

Paddack, 27, had a great debut with the Padres in 2019, making 26 starts with a 3.33 ERA. His results fell off in the next two seasons, and he dealt with an elbow strain late in the 2021 season, but the Twins still liked him enough to acquire him as part of their return for Taylor Rogers. He was only able to make five starts before landing on the shelf. Their faith doesn’t seem to have wavered, as they recently signed him to a three-year extension. The Twins have a solid rotation on paper, but nearly the entire group landed on the injured list at some point in 2022. Kenta Maeda missed the whole season while rehabbing from an internal brace procedure, a modification of Tommy John surgery. Since injuries were the big story for the Twins in 2022, better health and/or better depth will be important in 2023.

Chad Green, Free Agent — June 2022

Green, 32 in May, spent the past seven seasons pitching for the Yankees. He tossed 383 2/3 innings in that time with a 3.17 ERA, striking out 32.5% of batters faced against a 6.3% walk rate. Unfortunately, he required Tommy John just a few months away from qualifying for free agency. He has yet to sign with a club, but players in this position often sign two-year deals that cover their rehab and give the team an extra year of control. If Green can find himself a deal like that, he could be a wild card down the stretch.

Casey Mize, Tigers — June 2022

Mize, 26 in May, was selected first overall by the Tigers in 2018. He posted a solid 3.71 ERA in 2021, but with disappointing underlying metrics. He only struck out 19.3% of batters faced and had a much higher 4.92 xERA, 4.71 FIP and 4.45 SIERA. After a dreadful 2022 season, the Tigers need to see how Turnbull, Mize, Skubal and Manning look this year before deciding how to proceed for the future.

Hyun Jin Ryu, Blue Jays — June 2022

Ryu, 36 in March, has oscillated between being injured and dominant for much of his career. He signed a four-year deal with the Blue Jays prior to 2020 and posted a 2.69 ERA that year, coming in third in the AL Cy Young voting. His ERA ticked up to 4.37 in 2021, and Ryu struggled even more last year before going under the knife. The Jays have a solid front four in their rotation but uncertainty at the back. Ryu is targeting a July return, and his health at that time could impact how the Jays approach the trade deadline.

Andrew Kittredge, Rays — June 2022

Kittredge, 33 in March, dominated in 2021 by posting a 1.88 ERA over 71 2/3 innings. He struck out 27.3% of batters he faced while walking just 5.3% of them and also got grounders on 53.5% of balls in play. He took a step back last year but made multiple trips to the injured list and likely wasn’t 100%. He’ll surely miss the first several months of the season but could jump into Tampa’s bullpen down the stretch.

Walker Buehler, Dodgers — August 2022

Buehler, 28, has an excellent track record for the Dodgers, having posted a 3.02 ERA in 638 1/3 innings. He’s struck out 27% of opponents while giving out free passes to just 6.3% of them. The Dodgers will have to get by without him for the majority of 2023, though there’s a chance he could be a late addition to the roster if all goes well. His August surgery makes him roughly one year behind Glasnow, who was able to return late in 2022. However, Glasnow’s procedure was August 4th of 2021 while Buehler’s was on the 23rd of last year. Still, if the Dodgers make a deep postseason run, that could give Buehler the runway he needs to make a landing this year.

September 2022 Or Later: Shane Baz, Anthony Gose, Scott Effross, Tyler Matzek, Bryce Harper

These players face longer odds of making an impact since their surgeries were so late in the year. The major exception is Harper, since position players require less recovery time than pitchers. Harper is hoped to be able to return to the Phillies around the All-Star break as a designated hitter, with a chance of returning to the field later in the campaign.

Rangers Exercise Option On José Leclerc

By | at

The Rangers announced that they have picked up their option on reliever José Leclerc. He will stick with the team and make a $6MM salary in 2023.

Leclerc had a dominant season in 2018, putting up a 1.56 ERA over 59 appearances while striking out 38.1% of batters faced. That included high leverage work, as he racked up 12 saves and 15 holds that year. It was enough for he and the club to agree to a four-year, $14.75MM extension with a pair of club options for 2023 and 2024. Unfortunately, he scuffled to a 4.33 ERA in 2019 and then missed most of 2020 and 2021 due to Tommy John surgery.

He returned healthy in 2022 and seemed to have a bit of rust at first, posting a 4.37 ERA through early August along with a 20.6% strikeout rate. However, he finished quite strong, posting a 1.44 ERA the rest of the way while striking out 33.7% of batters faced. That also included a return to high leverage situations, with Leclerc earning seven saves and four holds on the season, most of those down the stretch. That latter sample is just 25 innings but more closely resembles his form from 2018.

The Rangers have decided to make a $5.25MM bet that Leclerc’s work over the final couple months of the season can be carried over into 2023. They could have bought him out for $750K but will instead pay him a $6MM salary. If he does indeed stay in strong shape next year, they could retain him again in 2024 with another club option, that one valued at $6.25MM with another $750K buyout.

For the Rangers, their bullpen was middle of the pack, putting up a 3.72 ERA that was 12th in the majors. Matt Moore is set to reach free agency after a successful transition from the rotation to the ’pen, but the club has prevented the relief corps from being further weakened by keeping Leclerc around.

Previewing Upcoming Club Option Decisions: American League

By | at

Yesterday, MLBTR checked in on the status of seven players who have vesting options in their contracts for the 2023 season. Each can (or already has) lock in some guaranteed money or the right to opt out of their current deal based on their workload or finish in awards voting this year.

Over the next two days, we’ll turn our attention to players with less of a say over their contractual status. A host of contracts around the league contain club options for 2023. Some of them will be easy decisions one way or the other, while there are others that’ll be more borderline calls. With teams having to make these calls a little over two months from now, it’s worth taking a look at how these players are performing in 2022.

Today, we’ll start with the American League. We’ll follow up with a look at the Senior Circuit tomorrow.

Orioles

Baltimore signed Lyles to a $7MM guarantee last winter, taking the form of a $6MM salary for 2022 and at least a $1MM buyout on next year’s option. He’s been a fine back-end starter, working to a 4.35 ERA across 130 1/3 innings. Lyles has below-average strikeout, swinging strike and ground-ball rates, but he leads the club in innings pitched and is throwing plenty of strikes. He’s also drawn strong reviews for his work in the clubhouse with the team’s younger arms. A $10MM call is borderline for a 4th/5th starter type, but the Orioles have almost nothing on the books next season and could keep him around as a veteran stabilizer.

Red Sox

  • James Paxton, SP (team must decide on consecutive $13MM options this offseason; Paxton would have $4MM player option for 2023 if club declines)

Paxton signed a convoluted deal last winter that reflected his atypical situation. A mid-rotation caliber starter when healthy, he’s made just six starts over the past three years and hasn’t pitched in an MLB game since undergoing Tommy John surgery last April. He’s making $6MM this season and could be a rotation option for a team that’ll see each of Nathan Eovaldi, Michael Wacha and Rich Hill hit free agency. The club will have to decide whether to trigger consecutive $13MM options (essentially a two-year, $26MM pact) this winter. If they decline, Paxton could opt in to a $4MM salary for 2023 or test free agency. How things play out largely depends on how Paxton looks down the stretch. Manager Alex Cora recently told reporters the southpaw will throw a simulated game on Friday and could soon head out on a minor league rehab appearance (link via Chris Cotillo of MassLive).

  • Hirokazu Sawamura, RP (team holds option currently valued at $3.6MM; Sawamura holds player option for 2023 currently valued at $1.8MM if club declines)

Sawamura signed a two-year, $3MM guarantee with the Red Sox over the 2020-21 offseason. The deal also included a club option for 2023 valued anywhere between $3-4MM, depending on whether Sawamura held his roster spot and based on his number of appearances. MLBTR has confirmed that escalators have already pushed the value of the club option to $3.6MM; that price escalates by an additional $100K for reaching each of 45, 50 and 60 appearances this season. (He’s presently at 43 games). If the team declines, Sawamura would have the right to trigger a player option currently valued at $1.8MM. As with the club option, the player option price escalates by $100K for reaching 45, 50 and 60 appearances. If both sides bypass their respective options, Sawamura would receive a $1MM buyout.

It seems likely that Sawamura’s team option price will fall somewhere in the $3.8MM – 3.9MM range, with a $1.8MM gap between the value of the club and player options. That’s an acceptable price to pay for a solid reliever, albeit one who’s been relied upon more in lower-leverage innings. Sawamura has a 3.14 ERA in 97 1/3 innings since coming stateside, striking out a decent 23% of opponents with a strong 51.7% ground-ball rate. He’s had issues throwing strikes consistently, but he’s an affordable power arm for a middle innings group that has been one of the team’s biggest weaknesses. That the Red Sox haven’t given Sawamura much high-leverage work in spite of their bullpen struggles is enough of a red flag to put this one in some doubt, but it seems likelier they’ll keep him around.

Yankees

Severino barely pitched between 2019-21 because of injuries, including a Tommy John recovery. He returned to the rotation this season and pitched to an impressive 3.45 ERA through 16 starts before suffering a lat injury that’ll cost him at least two months. The injury history is a real concern, but Severino still looks like an above-average starter when healthy. He’s averaged around 96 MPH on his fastball, struck out 27.2% of opposing hitters and has a tiny 7.2% walk rate. The Yankees would have to be very pessimistic about his health outlook to buy out his age-29 season, particularly since it’s only a $12.25MM decision once the buyout price is taken into account.

Rays

Kiermaier hit .228/.281/.369 over 221 plate appearances before suffering a season-ending left hip injury. It’s the latest in a long line of major health issues for the 32-year-old, and the Rays are planning to buy out the three-time Gold Glove winner. It’s possible the team tries to circle back at a lower price point, but the career-long Ray is likely to hit the open market for the first time in his career.

Blue Jays

The Jays just acquired Bass from the Marlins at the trade deadline, fortifying their bullpen with a productive middle-innings arm. Bass has an excellent 1.49 ERA through 48 1/3 innings on the year, striking out 26.2% of opponents against just a 5.9% walk rate. It’s a career-best season at age 34, but Bass has a sub-4.00 ERA for five years running. He’s an underrated bullpen piece, and the Jays are sure to bring him back for what amounts to a $2MM decision.

White Sox

This is as easy a call as any team will have to make this winter. Anderson has been one of the game’s better players four years running. He’s an elite contact hitter and baserunner, and he’s cemented himself as the Sox’s franchise shortstop. His 2022 season has been dinged by injuries, including a recent hand ligament tear that’ll cost him most of the remaining schedule. Frustrating year aside, Anderson has hit at a quality .301/.339/.395 clip this season and been an All-Star caliber performer in prior years. The White Sox are keeping him around next year, and they can do the same in 2024 via $14MM option.

Harrison signed a one-year deal in Spring Training and got off to a dreadful start. The veteran utilityman has turned things on since the calendar flipped to June, though, and he now carries a roughly league average .242/.312/.385 line through 281 plate appearances. The Sox will have to make a $4MM call this offseason on whether to bring him back for 2023. They’ll probably look for an upgrade at second base, but that’s a reasonable enough sum to dedicate to a quality infielder off the bench. Chicago already has Leury García making decent money in that role, and they might prefer to focus their finances on adding to the back of the rotation and bringing back star first baseman José Abreu.

Guardians

Shaw is a longtime member of the Cleveland organization, having spent seven of his 11 MLB seasons there. He’s a durable bullpen workhorse who’s clearly a favorite of the coaching staff and front office, but his 2022 results have not been good. The 34-year-old righty owns a 5.36 ERA across 40 1/3 innings. He’s only striking out 17.7% of opponents, walking batters at an elevated 11.6% clip and has had some home run issues. The Guardians seem likely to go in another direction this offseason.

Twins

Sanó is a longtime member of the organization who’s capable of carrying a lineup with his power at his best. His platform season has been a disaster, though, and the Twins are sure to buy out his option. The 29-year-old underwent surgery to repair a meniscus tear in his knee in May. He returned briefly but went back on the 60-day injured list last week with additional knee concerns. It’s not clear whether he’ll make it back this season. Sanó has an .083/.211/.133 line in 20 games this year after slightly above-average offensive performances in 2020-21.

Just as Sanó’s option is certain to be bought out, Gray’s is a no-brainer to exercise. Minnesota acquired the right-hander from the Reds in Spring Training, sending last year’s first-round pick Chase Petty to Cincinnati. Gray lost some time on the injured list, but he’s posted an impressive 3.19 ERA with slightly above-average peripherals through his first 16 starts in a Twins uniform. A mid-rotation starter of his caliber is a solid bargain at the cost of his option, which played into the fairly high asking price the Twins had to relinquish in the trade.

The Twins bought low on Bundy on a one-year free agent deal, hoping he’d rebound from a dismal 2021 and look more like the mid-rotation arm he resembled in 2020. That hasn’t really transpired, as the right-hander has a 5.01 ERA through 93 1/3 innings. He’s averaging a personal-low 89.2 MPH on his fastball, and while he’s throwing plenty of strikes, that lack of velocity has been reflected in both his 18.6% strikeout rate and higher than average home run rate. It seems likely the Twins will decline the option and reallocate that $10MM elsewhere, particularly with the recent acquisition of Tyler Mahle and Kenta Maeda’s expected return reducing the urgency to add to the rotation next season.

Astros

Acquired in a one-for-one deadline swap that sent Jake Odorizzi to Atlanta, Smith is having a generally disappointing year. He has a 4.17 ERA through 41 innings, striking out a personal-worst 24.1% of batters faced with a career-high 11.2% walk rate. Smith was an effective late-game arm as recently as a season ago and is still generating swinging strikes at a quality 14.2% clip, but the $12MM price tag seems likely to be too hefty given the mediocre strikeout and walk numbers.

Athletics

Piscotty has spent five seasons in Oakland after being acquired from the Cardinals heading into the 2018 campaign. He had an excellent first season in green and gold, but he’s been a well below-average hitter fours years running now. Going back to the start of 2019, Piscotty has a .231/.288/.380 line in just under 900 trips to the plate. He’s sure to be bought out and could be looking at minor league offers next winter.

Mariners

  • Ken Giles, RP ($9.5MM option, $500K buyout)

Seattle signed Giles to a two-year deal knowing he’d miss all of 2021 recovering from Tommy John surgery. Unfortunately, hopes of a year two payout have been largely derailed by a finger issue that delayed his season debut and some shoulder tightness that has kept him out of action for the past month. Giles has thrown just 4 1/3 innings in a Seattle uniform, surrendering only one hit but four walks with six strikeouts. He’s averaged 94.8 MPH on his fastball, still solid but down from the 96.9 MPH range he showed during his incredible 2019 season with the Blue Jays. There’s a non-zero chance Giles returns — he’s currently on a rehab assignment in Triple-A — and dominates down the stretch to make Seattle think about the option. For the moment, though, it’s trending towards a buyout.

Rangers

Texas signed the 34-year-old Richards to a one-year guarantee over the offseason, hoping he’d build off the promise he showed in a late-season bullpen stint with the Red Sox. That hasn’t panned out, as he has a 5.35 ERA across 38 2/3 innings of relief. Richards has an excellent 52.1% ground-ball rate, but he’s not missing as many bats as one would like and he’s giving up a lot of hard contact. Texas seems likely to buy him out.

Texas signed Leclerc to an early-career extension in 2019, locking him in after a 1.56 ERA season the year before. He struggled with his control the following season, then missed virtually all of 2020-21 battling elbow issues that eventually culminated in Tommy John surgery. Leclerc returned to the mound in June but has a 4.01 ERA with a personal-low 20.4% strikeout percentage in 24 2/3 innings of generally low-leverage work. He’s still throwing hard and missing plenty of bats with his slider, so there’s a chance Texas takes an optimistic view and keeps him around. His deal also contains a $6.25MM option for 2024, so he’d be under control for multiple seasons if the Rangers are willing to give him a bit of a longer leash. This feels like it could go either way depending on how he performs down the stretch.

The Rangers signing of Calhoun to a one-year deal over the winter hasn’t panned out. He’s hitting .211/.269/.363 through 350 plate appearances and is currently on the injured list with a heel issue. It’s a second straight below-average season for the veteran outfielder, who’ll be 35 in October. The Rangers will almost assuredly decline the option and look elsewhere in right field as they aim for legitimate competitiveness in 2023.

Rangers Activate Jose Leclerc From Injured List

By | at

The Rangers announced they’ve reinstated reliever José Leclerc from the 60-day injured list. He’ll be active for tonight’s contest in Detroit, potentially setting him up for his first big league appearance in two years. Texas also activated reliever Brett Martin and outfielder Steele Walker from the COVID-19 IL. Walker and left-hander Kolby Allard have been optioned to Triple-A Round Rock to free active roster space. Tyson Miller, who’d been brought up as a designated COVID substitute, was taken off the 40-man roster and returned to the minors after two appearances.

Leclerc’s return is the biggest development for the Rangers, as it marks the end of a 15-month rehab process. The right-hander underwent Tommy John surgery just before Opening Day last year, costing him a season and a half worth of action. That came on the heels of a 2020 campaign in which he was limited to two appearances because of a shoulder strain, meaning he hasn’t seen extended action since 2019.

Before the health concerns threw his career off track, Leclerc looked as if he might emerge as one of the sport’s better late-inning arms. He’s shown swing-and-miss stuff throughout his career, but he was particularly effective in 2018. Leclerc posted a 1.56 ERA in 57 2/3 innings that season, striking out an elite 38.1% of opponents with a personal-low 11.2% walk rate. The following offseason, Texas signed him to a $14.75MM guarantee to buy out a pair of potential free agent seasons.

Leclerc’s control regressed in the first year of the deal, and he pitched to an underwhelming 4.33 ERA through 68 2/3 innings. Injuries have cost him the next two and a half seasons, but he’ll finally step back into the bullpen for skipper Chris Woodward. He tossed nine innings over as many appearances on a minor league rehab stint before returning to the MLB roster.

The 2022 season is the final guaranteed year of the aforementioned extension. Leclerc is making $5.25MM, and the club holds successive options for the next two seasons. They’ll have to decide on a $6MM option or a $750K buyout at the end of this year, making the next few months particularly critical for Leclerc’s long-term earning potential.

Rangers Trade Yonny Hernandez To Diamondbacks

By | at

The Rangers have set their Opening Day roster, announcing a series of transactions that includes the trade of infielder Yonny Hernandez to the Diamondbacks in exchange for minor league outfielder Jeferson Espinal. Arizona has designated right-hander Humberto Mejia for assignment in a corresponding roster move.

Texas also designated infielder Sherten Apostel for assignment and selected the contracts of veterans Matt Bush, Charlie Culberson and Greg Holland. Right-hander Garrett Richards, meanwhile, has been placed on the 10-day injured list due to a blister issue, while righty Jose Leclerc has been placed on the 60-day IL as he continues recovering from last March’s Tommy John surgery.

Hernandez, 24 next month, made his big league debut with Texas last year and batted .217/.315/.252 in 166 trips to the plate. His work in Triple-A, where he slashed .250/.424/.323 in 261 plate appearances, was far better. Hernandez walked at a gaudy 20.3% clip in Triple-A last season and has a penchant for drawing free passes and making contact, albeit rarely with any real power. He’s walked in more than 15% of his professional plate appearances and also possesses plenty of speed, evidenced by 23 steals in the minors and another 11 in the big leagues last season.

Hernandez has experience all over the infield and has all three minor league option years remaining, so he’ll give the D-backs some flexibility and versatility not only in 2022 but for the foreseeable future. He can be controlled for at least the next six seasons, and possibly more, depending on how much big league time he accrues while he has those options remaining.

Espinal, 19, batted a combined .259/.340/.357 between Rookie ball and Low-A last season, with the vast majority of his production coming at the lower of those two levels. Eric Longenhagen and Brendan Gawlowski wrote at FanGraphs back in January that Espinal has 70 speed on the 20-80 scale but a long swing and serious questions about his overall hitting profile. Espinal did swipe 16 bases in 19 tries last season, but he’ll have a ways to go before the Rangers can even hope to have him as a viable option in the outfield.

Apostel, 23, went 2-for-20 in his big league debut back in 2020 and didn’t appear in the Majors last season. He’s primarily a third baseman but has experience at first base as well. Apostel posted a lackluster .235/.321/.416 across three levels last season, topping out with a sub-par showing in Triple-A Round Rock. The Rangers will have a week to trade Apostel, place him on outright waivers or release him.

As for the D-backs, they’re in the same boat with regard to the 25-year-old Mejia. He’s tallied 32 1/3 big league innings but struggled to a 6.68 ERA in that time, and last year’s work in the minors was not decidedly more encouraging. In 103 2/3 frames between Double-A and Triple-A, Mejia pitched to a combined 5.12 ERA with a 22.1% strikeout rate and 8.2% walk rate. Another club in need of some pitching depth might take a look in a small trade or via waivers, but Mejia has not yet found too much success above A-ball.

8 Post-Tommy John Pitchers Who’ll Impact Next Year’s Market

By | at

We’ve grown accustomed to seeing headline after headline indicating that a pitcher is slated to undergo Tommy John surgery in today’s game. The procedure has become so commonplace, in fact, that it’s no longer surprising to see teams guarantee multi-year deals to rehabbing pitchers who’ll be sidelined for a full season of that contract as they work back from the injury. Such deals have produced varying levels of success in the past. Nathan Eovaldi’s two-year deal with the Rays worked out great; Drew Smyly didn’t pitch for the Cubs and posted a 6.24 after being traded to the Rangers.

Heading into the 2022 season, there are a handful of notable pitchers who were either signed under just that circumstance or are now playing for a contract on the heels of a Tommy John surgery that, hopefully, is more or less in the rearview mirror. A strong rebound will position any of this bunch either as a prominent member of next winter’s free-agent crop or, in some cases, to have a lucrative 2023 club option picked up. Here’s a look at a handful of Tommy John recoveries that could have a notable impact on next year’s market.

Starting Pitchers

Mike Clevinger: A marquee addition by the Padres at the 2020 trade deadline, Clevinger made only four regular-season starts and a one-inning postseason cameo before requiring Tommy John surgery in the 2020-21 offseason. San Diego, knowing he’d miss the entire 2021 season, signed him to a two-year, $11.5MM deal that paid him $2MM during his rehab season but will more heavily compensate him in 2022, now that he’s expected to be back to full strength. It was the second Tommy John procedure of Clevinger’s career, as he also had the surgery as a minor leaguer back in 2012.

There’s little questioning Clevinger’s talent, as the now-31-year-old righty was one of the most effective starters in all of baseball from 2017 until the time of his injury in 2020. In 489 1/3 innings over that stretch, Clevinger posted a 2.96 ERA while punching out 28% of his opponents against a 9% walk rate. Among big league pitchers with at least 400 innings thrown during that time, Clevinger ranked seventh in ERA and 14th in FIP (3.39). That said, he’s also only reached 130 innings in a big league season on one occasion, when he threw an even 200 frames in 2019.

That relatively limited workload, coupled with this being Clevinger’s second Tommy John procedure, will surely impact his free agency next winter to an extent. That said, a strong and healthy season out of the righty will still position him as one of the top arms on next winter’s market. Clevinger, teammate Joe Musgrove, Sean Manaea and Noah Syndergaard are among the more prominent free agents still in their early 30s next winter (to say nothing of older veterans with contract options or opt-outs, such as Jacob deGrom, Justin Verlander and Charlie Morton).

James Paxton: Paxton isn’t necessarily playing for a free-agent contract. He signed a complicated multi-year deal with the Red Sox that’ll pay him $6MM in 2022 before he can either trigger a $4MM player option or the team can exercise a pair of $13MM club options for the 2023-24 seasons. For luxury-tax purposes, that should be considered a two-year, $10MM deal, as the player option for 2023 is considered to be guaranteed money. Of course, there’s also the possibility that with a healthy season, the contract will effectively balloon to a contract that pays Paxton $32MM over a three-year term. The deal contains further incentives, as Paxton could boost those 2023-24 salaries by $250K apiece for reaching 12, 14, 16 and 18 starts.

It’s a heavily incentive-laden deal that speaks both to the considerable risk in signing Paxton and the considerable upside he’ll bring to Boston. A healthy Paxton is a high-quality big league starter, evidenced the career 3.50 ERA he carried into an injury-ruined 2020 season with the Yankees. Among the 149 big league starters to toss at least 200 innings from 2017-19, Paxton’s 30.1% strikeout rate ranked seventh, and his 7.3% walk rate was markedly better than league average. His 22.7 K-BB% was among the best in the game, as were his strong ratings in the eyes of fielding-independent metrics like FIP (3.26) and SIERA (3.45).

Since that 2019 season, however, Paxton has undergone back surgery, missed significant time with a forearm strain and eventually undergone Tommy John surgery. Earlier in his career, he’d dealt with lat, forearm and pectoral injuries, among a litany of smaller-scale issues.

There’s probably a scenario where Paxton pitches well enough to turn down his $4MM player option even if the Red Sox decline the effective two-year, $26MM option they hold over him. (We saw a comparable situation play out with Yusei Kikuchi earlier in the winter.) That said, the ideal scenario for Paxton and the Sox is that he pitches well enough to reestablish himself as a quality MLB hurler and boost those two club options to $14MM apiece in total value in the process.

Paxton underwent his Tommy John procedure in late April, so he’s not likely to be ready to help the Red Sox at the beginning of the season. By late May or June, however, he could represent a boost to a rotation that is not exactly shy of other injury concerns.

Justin Verlander: Even though he hasn’t pitched since undergoing Tommy John surgery, Verlander still got a hefty $25MM guarantee from the Astros — plus a conditional $25MM player option that kicks in if he reaches 130 innings pitched. The two-time Cy Young winner and former AL MVP has a track record that speaks for itself; when we last saw Verlander in a full, healthy season, he was edging then-teammate Gerrit Cole for the 2019 AL Cy Young Award.

Verlander has said in the past that he hopes to pitch into his 40s, and he has a good chance at doing so if he can bounce back this coming season. He’ll turn 39 later this week, and if he goes out and looks anything like he did from 2015-20 — 1010 innings, 2.94 ERA, 29.7% strikeout rate, 6% walk rate — Verlander will likely turn down that $25MM option, or at least leverage it into a new multi-year arrangement with the ’Stros. He was just promised a $25MM guarantee despite having thrown only six innings since Opening Day 2020, so there’s little reason to accept that he’d take a year and $25MM on the heels of a healthy return effort at Minute Maid Park.

Noah Syndergaard: Perhaps it’s not quite fair to label Syndergaard as a Tommy John rehabber; after all, he did make it back to the mound with the Mets late in the 2021 season — albeit for only two innings. That said, this is Thor’s first full season back from that ligament replacement procedure, and he’ll be pitching for a big contract next winter from the moment he suits up in Orange County. Signed by the Angels to a one-year, $21MM contract, Syndergaard will be pitching with a team other than the Mets for the first time in his big league career.

It’s a hefty price to pay, particularly considering the fact that Syndergaard had rejected an $18.4MM qualifying offer, but his career to date is all the evidence needed to suggest that at his best, Syndergaard is plenty worth that gamble. He’s never walked more than 6.1% of his opponents in a given season and has never failed to strike out a batter per inning. Few pitchers can match Syndergaard’s blend of pure velocity, missed bats and impeccable command, and he manages all that while still turning in a ground-ball rate that’s well higher than the league average.

Syndergaard has always felt like he’s one step away from solidifying himself as a bona fide ace, and as Robbie Ray showed in winning the AL Cy Young Award this season, one dominant season for a player with this type of track record can result in a nine-figure payday if things break right. The market has already proven to value Syndergaard at more than $20MM per year, and given that he’d be 30 years old in 2023, it’s not hyperbole to suggest that he’s pitching for a $100MM contract this season.

Luis Severino: As with Syndergaard, Severino may not quite fit the criteria for this list. The 27-year-old (28 later this week, on the same day Verlander turns 39) returned to give the Yankees six innings out of the bullpen late in the 2021 season, and his protracted absence from the team’s pitching staff cannot be solely attributed to Tommy John surgery. Severino has also battled groin, shoulder and lat injuries along the way. That said, Severino really hasn’t pitched since undergoing Tommy John surgery in Feb. 2020, and it’s that operation that is the primary reason for his absence over the past two seasons.

Severino isn’t yet slated to hit the open market at season’s end — at least not before the Yankees make a call on a $15MM club option or a $2.75MM buyout. The resulting $12.25MM net decision would be a straightforward one for general manager Brian Cashman if Severino at all looks like his former self. From 2017-18, Severino gave the Yankees 384 2/3 innings of 3.18 ERA ball with outstanding strikeout and walk rates, prompting the team to sign him to a four-year contract extension that promised him $40MM.

That deal looked like a bargain for the team at the time but has since gone south, due largely to repeated injury woes. Severino made a combined 63 regular-season starts for the Yankees in 2017-18, looking every bit like a foundational piece to the pitching staff, but he’s combined for just 25 starts and another 18 relief appearances in the five seasons surrounding that brilliant run.

With a big season in 2022, Severino could still see that $15MM option picked up, and if he can remain healthy into 2023, he’d hit the open market heading into his age-30 season. There’s a long way to go before that scenario becomes reality, however.

Relievers

Tommy Kahnle: Signed by the Dodgers to a two-year, $4.75MM contract last offseason, Kahnle was never expected to contribute in 2021 — hence the backloaded nature of his contract, which will pay him $3.45MM in 2022. The hard-throwing righty only managed one inning for the 2020 Yankees, meaning this coming season will be the first since 2019 in which he’ll potentially pitch anything resembling a full workload.

The 32-year-old Kahnle has been inconsistent but has dominated more often than he’s struggled. From 2016-20, he logged a combined 3.48 ERA, 32.9% strikeout rate and 9.9% walk rate while averaging 97.1 mph on his heater. That includes a disastrous but also fluky-looking 2018 campaign in which he was tattooed for a 6.56 ERA in 23 1/3 frames. From 2016-20, Kahnle’s 32.9% strikeout rate ranks 17th among the 155 relievers to have thrown at least 150 innings, while his 15.9% swinging-strike rate is tied for sixth.

Kahnle’s Tommy John surgery came way back on Aug. 5, 2020, so there should be no restrictions on him by the time the season gets underway. He’ll be heading into his age-33 season next winter, and a return to his vintage form should position him as one of the top relievers on a free-agent market that is lacking in big-name right-handed relievers.

Ken Giles: Like Kahnle, Giles was signed by the Mariners — two years, $7MM — knowing full well that he would not pitch in 2021. Unlike Kahnle, his contract includes a club option for the 2023 season, which is valued at $9.5MM (with a $500K buyout).

Many of the same superlatives that apply to Kahnle apply even more so to Giles. His 18% swinging-strike rate, for instance, tops Kahnle and sits third among the 155 relievers who totaled at least 150 frames from 2016-20. His 3.33 ERA in that time is a bit more toward the middle of the pack, but Giles misses bats, induces chases outside the zone and throws as hard as nearly any reliever in the sport. He’s had a pair of 4.00-something ERAs sprinkled in amid a series of pristine marks throughout his big league career. Those two blemishes have coincided with spikes in his average on balls in play and dips in his strand rate.

On the whole, Giles is a power arm who can pile up strikeouts in droves. He’s a sometimes forgotten piece of the puzzle when looking at the 2022 Mariners and their hopes of contending, but he’ll join a deep bullpen mix that also features Diego Castillo, 2021 breakout closer Paul Sewald, former Marlins stopped Drew Steckenrider (who enjoyed a tremendous rebound in 2021) and the underappreciated Casey Sadler, who notched a 0.67 ERA in 40 1/3 innings last year.

A healthy Giles would very likely see that $9.5MM club option for the 2023 season picked up, and at his best, he’s a bargain at that price. If Giles is pitching well but things go south for the Mariners, teams will come calling at the trade deadline. Of course, the Mariners are hoping to be squarely in the postseason mix, and they’re likely not done with their offseason shopping just yet.

Jose Leclerc: Armed with a fastball in the mid to upper 90s, Leclerc’s ability to return to form (or his lack thereof) will have major implications for the Rangers moving forward. His four-year, $14.75MM contract extension includes a $6MM club option for the 2023 season and a $6.25MM option for the 2024 season. A rebound effort makes that 2023 option a no-brainer for the Rangers to pick up as they hope to ride a hyper-aggressive offseason into their next competitive window.

Leclerc, 28, has fanned just shy of a third of the hitters he’s faced so far in his big league career and has only allowed a dozen homers in 189 Major League innings (0.57 HR/9). His 14.9% walk rate is far too high, but he looked to be making considerable strides in that department in 2019 when he posted a sub-2.00 ERA, a 38.1% strikeout rate and an 11.2% walk rate. He’ll be a highly intriguing lottery ticket on next year’s market if he pitches poorly enough that the Rangers buy that option out (or if they do so on the heels of another injury). If he rebounds, he’ll be a bargain piece of an on-the-rise Rangers club in 2023-24.

Jose Leclerc To Undergo Tommy John Surgery

By and | at

Rangers closer Jose Leclerc will undergo Tommy John surgery and miss the 2021 season, general manager Chris Young announced to reporters Monday (Twitter link via MLB.com’s Kennedi Landry).

Leclerc has battled elbow soreness since last week, so this news isn’t surprising, but it will rob him of an entire season and the Rangers of their best reliever. The 27-year-old threw just two innings last season as he dealt with a strain of his right teres muscle, and this latest injury will continue to throw a once-promising career off course.

Between 2016-19, Leclerc threw 187 innings of 3.16 ERA ball, and though he walked almost 15 percent of batters during that span, he helped offset that with a 33 percent strikeout rate and a fastball that averaged upward of 95 mph. The Rangers were so impressed with Leclerc’s work that they signed him to a four-year, $14.75MM extension before 2019. It looked like a worthwhile gamble at the time, but it hasn’t worked out as hoped for Texas because of Leclerc’s arm troubles. His deal still includes one more guaranteed season, in which he’s also sure to miss time as he recovers from this surgery, and two years with club options for $6MM or more or buyouts worth $750K or less apiece.

With Leclerc done for the season, it’s unclear who will open the season as the Rangers’ closer. Ian Kennedy and Matt Bush look like the most logical candidates, as they have game-ending experience and the Rangers selected their contracts over the weekend. Taylor Hearn and Josh Sborz are also among those who could be in the mix. Regardless, the loss of Leclerc is a significant one for the Rangers.

Jose Leclerc To Miss “Extended Time” With Elbow Soreness

By | at

Rangers closer Jose Leclerc is suffering from elbow soreness that will cause the righty to miss “extended time,” according to Evan Grant of the Dallas Morning News (Twitter link) and multiple reporters.  Leclerc has already left the Rangers’ Spring Training camp and headed to Texas for further examination.  In more unfortunate injury news, southpaws Joely Rodriguez and Brett Martin will also begin the season on the injured list, though their absences aren’t expected to last as long.

With Jonathan Hernandez already out through at least the first part of April due to a UCL sprain, Leclerc’s injury represents another long-term hit to the Texas bullpen.  Any mention of an elbow problem naturally raises the concern of Tommy John surgery, which would keep the 27-year-old Leclerc out of action until midway through the 2022 season.

This is the second significant injury in as many years for Leclerc, who pitched in only two games last season due to a tear of his right teres muscle.  His return to action was marked by a late arrival at camp due to visa issues, and then Leclerc didn’t have his usual velocity over 3 2/3 Cactus League outings, which perhaps isn’t unexpected as he was rebuilding his arm strength.

Despite it all, Leclerc was the provisional favorite to enter the season as the Texas closer.  He was first promoted to the job back in 2018, during a season that saw Leclerc post a 1.56 ERA/2.60 SIERA and a whopping 38.1K% (eighth-highest of any pitcher in baseball with at least 50 IP) over 57 2/3 frames out of the Rangers’ bullpen.  His performance took a step back in 2019, due in part to both an increase in walks and a big decrease in batted-ball luck (a .306 BABIP in 2019, as opposed to a .211 BABIP in 2018), but it should be noted that most of Leclerc’s struggles that year were contained to the month of April.

Prior to that 2019 season, Leclerc signed a contract extension that paid him a guaranteed $14.75MM through the 2022 season, with the Rangers holding club options on his services for both 2023 ($6MM, $750K buyout) and 2024 ($6.25MM, $500K buyout).  While not a huge financial investment, this extension will end up looking like something of a bust for Texas should the worst come to pass and Leclerc does require TJ surgery.

Rodriguez (sprained ankle) and Martin (back) haven’t yet pitched during Spring Training, but both left-handers could end up spending a relatively short time on the IL, perhaps even just a minimal 10-day absence.  Their returns will be greatly welcomed by a Rangers bullpen that is now suddenly thin on arms.  It remains to be seen who will be the first choice for save with both Leclerc and Hernandez out, and the role could fall to minor league signings Ian Kennedy or Matt Bush.

AL Notes: Rangers, Angels, Quatraro

By | at

Some notes from the American League:

  • The Rangers reinstated a trio of players from the 60-day injured list this afternoon, per a team announcement. Right-hander José Leclerc and left-handers Brock Burke and Joe Palumbo are all back on the 40-man roster, bringing Texas’ tally to 35. Those three relievers only combined for 4.1 innings in 2020. Leclerc suffered a teres major strain in July, while Burke underwent season-ending shoulder surgery in February. Palumbo, meanwhile, battled a bout of ulcerative colitis.
  • The Angels and assistant general manager Jonathan Strangio are parting ways, reports Fabian Ardaya of the Athletic (Twitter link). The Harvard alum’s contract expired October 31 and was not renewed. There’s been quite a bit of turnover in the Halos’ front office in recent weeks. The club fired general manager Billy Eppler, while former advisor Tony La Russa signed on as White Sox manager. As Ardaya notes in a follow-up tweet, Strangio had taken on a larger role in day-to-day baseball operations in the wake of Eppler’s firing. He informed the organization in August he’d be leaving at the end of the season for family reasons, Ardaya adds.
  • Before deciding on A.J. Hinch, the Tigers interviewed Rays bench coach Matt Quatraro in their managerial search, reports Marc Topkin of the Tampa Bay Times. Quatraro also drew some consideration from the Pirates and Giants for their respective vacancies last offseason. The 46-year-old has been on Kevin Cash’s coaching staff since the start of the 2018 season.

Kluber, Leclerc, Santana Won’t Return To Rangers This Season

By | at

SEPT. 9: Santana underwent elbow surgery and will miss seven to eight months, TR Sullivan of MLB.com tweets. That could jeopardize at least some of Santana’s 2021 campaign, which will be his final arbitration-eligible season. After Santana made a prorated $3.6MM this season, the Rangers will have to decide whether to keep him on the heels of a rough year.

SEPT. 5: Three injured Rangers players are done for the season, as manager Chris Woodward told reporters (including Evan Grant of the Dallas Morning News) that Corey Kluber, Jose Leclerc, and Danny Santana won’t return to action in 2020.  Kluber and Leclerc were each already on the 45-day injured list with teres major problems, while Santana has been on the 10-day IL since August 28 due to a right elbow strain.

The Rangers expected all three to be key contributors this season, hoping for a repeat of Santana’s breakout 2019 numbers, Leclerc to return to his 2018 form after a somewhat shaky 2019, and for Kluber to bounce back from an injured-plagued 2019 season that ultimately closed the book on the former ace’s tenure in Cleveland.

Instead, Kluber pitched in just one inning of one game for Texas before hitting the IL with a grade 2 tear of the teres major muscle.  Leclerc only banked two games before suffering a strain in his own teres major muscle, while Santana has been limited to 63 PA in 15 games (and only a .145/.238/.273 slash line) thanks to two trips to the injured list.  A right forearm strain put Santana on the 10-day IL on August 2 and kept him out of action until the middle of the month.

Leclerc is under contract through at least the 2022 season, while Santana has one more year of arbitration eligibility remaining before hitting free agency in the 2021-22 offseason.  Santana obviously won’t earn much of a raise on his $3.6MM salary for 2020, but given how the Rangers (like many teams) are planning on a lower payroll next season, it is conceivable that Santana could be non-tendered and then pursued at a lower price than a salary in the ballpark of $3.6 or $3.7MM.

Of course, a big chunk of money will be coming off the Rangers’ books in the form of Kluber’s contract, as Texas is surely unlikely to exercise its $18MM club option on the veteran righty for the 2021 campaign.  With just 36 2/3 total innings pitched since the start of the 2019 season, Kluber will be hard-pressed to find anything more than a single guaranteed year on his next contract, though his track record could still land him another Major League deal.  We aren’t far removed, after all, from the dominant five-year stretch Kluber delivered in the Indians’ rotation from 2014-18 — 2.85 ERA, 10.1 K/9, 5.51 K/BB rate, two AL Cy Young Awards, and an average of 218 innings pitched.

Show all

MLB Trade Rumors is not affiliated with Major League Baseball, MLB or MLB.com

hide arrows scroll to top